High Court Grants Leave to Challenge HSE Wegovy Refusal

The High Court has granted permission to a teenager to pursue a full judicial review against the Health Service Executive following its refusal to fund the weight-loss medication Wegovy under discretionary hardship provisions. Delivered by Ms Justice Mary Rose Gearty, the ruling paves the way for a substantive hearing into whether health authorities acted irrationally or failed to take into account vital medical evidence. The case, brought by the minor applicant through his mother and next friend, highlights the continuing legal battles surrounding patient access to modern pharmaceuticals within Ireland's publicly funded health sector.

Overlooked Medical Factors in Hardship Assessment

The applicant, anonymised as Tom pursuant to court reporting conventions, sought reimbursement for the prescription drug following a series of complex health difficulties. The HSE issued a formal refusal on 19 May 2026, resting its decision on the grounds that the teenager suffered from three identified conditions for which an alternative treatment existed, while also expressing concern that approving the drug could open the door to numerous similar claims. However, his legal representatives argued that the decision was fundamentally flawed and breached his rights because evaluators failed to address a significant, rare underlying syndrome. Counsel submitted that this omission tainted the entire assessment, rendering the statutory decision irrational under established administrative law principles.

In her judgment, Ms Justice Gearty found that the applicant had established a stateable and arguable case that decision-makers either dismissed or entirely overlooked material medical evidence. The court noted that had this rare condition been properly appraised, it remains unclear whether the alternative medication would still have been considered appropriate or whether the precedent-setting floodgates argument would retain any force. By failing to confront this potentially pivotal diagnostic factor, the executive opened its administrative determination to legitimate legal question. In judicial review proceedings, administrative bodies are obliged to demonstrate that they have evaluated all relevant considerations before arriving at an adverse ruling.

The Legal Threshold for Judicial Review

Applications for leave to seek judicial review represent a preliminary screening stage under Order 84 of the Rules of the Superior Courts. In line with the long-standing precedent established by the Supreme Court in G v DPP [1994], an applicant must demonstrate that judicial review is the most appropriate remedy and satisfy the court that there is an arguable ground for quashing the impugned decision. While the bar is lower than that applied at a plenary trial, applicants must nonetheless present an intelligible basis supported by facts showing that public authority actions fell foul of statutory standards.

During the preliminary hearing, the HSE argued that courts should exercise substantial judicial restraint when dealing with resource allocation and medical reimbursement schemes. The executive contended that health policy and budgetary prioritisation must remain matters of administrative discretion rather than judicial intervention. While acknowledging the general principle that courts do not readily interfere with specialist clinical or allocation decisions, Ms Justice Gearty observed that doctrines of restraint do not insulate administrative procedures from review where material evidence appears to have been left out of the deliberative process.

Reimbursement Framework and Next Steps

The substantive dispute centres on provisions under Section 23 of the Health (Pricing and Supply of Medical Goods) Act 2013, which governs the statutory and discretionary supply of medicinal items outside standard reimbursement lists. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists such as Wegovy has placed growing strain on state reimbursement mechanisms, with health authorities closely monitoring overall fiscal exposure. Discretionary hardship schemes serve as an exceptional safety net for vulnerable patients, requiring decision-makers to strike a careful balance between broad public expenditure controls and acute, individual clinical circumstances.

As a result of the ruling, the applicant was granted leave to seek an order of certiorari to quash the HSE refusal of 19 May 2026, alongside standard residual legal relief. The court declined to grant leave for specific declaratory orders regarding the suitability of alternative pharmaceutical treatments, concluding that such declarations were unnecessary given that the trial judge retains broad latitude under residual relief provisions to fashion appropriate remedies. The High Court emphasised that the granting of leave does not constitute a final ruling on the ultimate merits of the claim, which will now proceed to a defended substantive hearing where the HSE will formally answer the allegations.